Insulin Out-of-Stock; Yet Another GLP/GIP Agonist; Digital Diabetes Tools Worth It?

Both generic and branded formulations of 10-mL vials of insulin lispro injection (Humalog) will be temporarily out of stock through the start of April, Eli Lilly announced.

A new study predicted global fertility, which has been declining in all countries, will continue to fall through the end of the century. (The Lancet)

In a phase I trial involving patients with obesity, an investigational, oral dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist yielded up to a 3.3% average placebo-adjusted weight loss at day 28, and with low rates of gastrointestinal events, according to developer Viking Therapeutics. A phase II trial is scheduled for later this year.

Ten-year mortality risk was high for people with sarcopenic obesity, data from the Netherlands showed. (JAMA Network Open)

More than half of patients with acromegaly on once-daily oral paltusotine achieved an insulin-like growth factor 1 level ≤1.0 times the upper limit of normal compared with only 5% on placebo in the phase III PATHFNDR-2 study, Crinetics Pharmaceuticals said. The novel drug also met all secondary endpoints in the trial.

Digital diabetes management tools may not be worth the high price-tag, a new report from the Peterson Health Technology Institute suggested.

In a JAMA Surgery viewpoint, one doctor wrote that metabolic bariatric surgery is “vastly” underused, given its excellent effectiveness and safety record.

A federal appeals court rolled back the Environmental Protection Agency’s ability to regulate per- and polyfluoroalkyl substances. (Reuters)

In a cohort with severe male factor infertility, FDA-cleared FemaSeed helped 24% of women become pregnant in a pivotal trial, maker Femasys said.

From statins to inhalers to insulin, nonadherence is the undoing of many “forever” drugs; will semaglutide (Wegovy) be the exception? (New York Times)

NYU Langone Health received a $15 million gift to further the treatment and study of endocrine disorders.

Some women are opting for in vitro fertilization over sex in an effort to take some control over getting pregnant. (New York Times)

Please enable JavaScript to view the

comments powered by Disqus.